To prioritize spending of taxpayers’ money on healthcare, one way is known as Health Technology Assessment (HTA). To evaluate treatments in terms of their utility, HTA institutions have measured the benefits of a treatment as the period by which one’s life is extended and improved. This may sound (too?) scientific but does not exclude making a choice on an economic threshold of a given medicine, according to this Stockholm Network paper. There is a lot of room for improving today’s threshold concept before it can actually be used, the authors argue. Thresholds would need to be made more explicit and transparent, while taking into consideration the quality of evidence for instance.
Read the full article here.
